cyclosporine has been researched along with Anemia, Refractory, with Excess of Blasts in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (91.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hao, YS; Liu, KQ; Qin, TJ; Xiao, ZJ; Xu, ZF; Zhang, Y | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Asano, Y; Mizoguchi, H; Mori, H; Niho, Y; Ohyashiki, K; Okamoto, T; Omine, M; Shimamoto, T; Teramura, M; Tohyama, K; Tomonaga, M; Uchiyama, T | 1 |
| Asano, S; Iseki, T; Nagamura, F; Ooi, J; Takahashi, S; Takahashi, T; Tojo, A; Tomonari, A; Uchimaru, K | 1 |
| Chatterjee, T; Choudhary, DR; Choudhry, VP; Dixit, A; Mahapatra, M; Mishra, P; Saxena, R | 1 |
| Chen, YR; Gong, M; Huang, FZ; Li, ZL; Ma, YG; Xu, SH | 1 |
| Broliden, PA; Dahl, IM; Hast, R; Hellstrom-Lindberg, E; Johansson, B; Juvonen, E; Kjeldsen, L; Oberg, G; Porwit-MacDonald, A; Sjoo, M; Tangen, JM; Uggla, B | 1 |
| Chen, S; Da, W; Gong, M; Guan, M; Jiang, B | 1 |
| Almeida, A; Daly, P; Dokal, I; McCloy, M; Roberts, IA; Vulliamy, T | 1 |
| Ando, M; Oshimi, K; Sugimoto, K; Tamayose, K | 1 |
| Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F | 1 |
| Itoh, M; Shimada, H; Tohyama, K; Yago, K | 1 |
5 trial(s) available for cyclosporine and Anemia, Refractory, with Excess of Blasts
| Article | Year |
|---|---|
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Alanine Transaminase; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival; Treatment Outcome; Vidarabine | 2003 |
Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan.
Topics: Adolescent; Adult; Aged; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Blood Platelets; Bone Marrow; Cell Lineage; Cyclosporine; Drug Evaluation; Erythrocytes; Female; Humans; Immunosuppressive Agents; Japan; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Pilot Projects; Treatment Outcome | 2003 |
Cyclosporin A in myelodysplastic syndrome: a preliminary report.
Topics: Adult; Aged; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Bone Marrow; Cyclosporine; Female; Humans; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Renal Insufficiency; Treatment Outcome | 2005 |
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antilymphocyte Serum; Atrial Fibrillation; Cyclosporine; Disease Progression; Female; Humans; Hypotension; Immunosuppressive Agents; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Remission Induction; Risk; T-Lymphocytes; Treatment Outcome | 2006 |
Treatment of myelodysplastic syndrome with cyclosporin A.
Topics: Adolescent; Adult; Aged; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Bone Marrow; Child; Cyclosporine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Rate; Treatment Outcome | 2007 |
7 other study(ies) available for cyclosporine and Anemia, Refractory, with Excess of Blasts
| Article | Year |
|---|---|
[Cyclosporine A in combination with thalidomide for the treatment of patients with myelodysplastic syndromes].
Topics: Anemia, Refractory, with Excess of Blasts; Cyclosporine; Humans; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2010 |
Resolution of Behçet's disease after HLA-mismatched unrelated cord blood transplantation for myelodysplastic syndrome.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Autoimmune Diseases; Behcet Syndrome; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Transplantation Conditioning | 2004 |
[Cyclosporine A based therapy for myelodysplastic syndrome].
Topics: Adolescent; Adult; Aged; Androgens; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Calcitriol; Cyclosporine; Drug Therapy, Combination; Erythropoietin; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Outcome | 2005 |
Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation.
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cyclosporine; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Immunosuppressive Agents; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Disappearance of chromosomal abnormalities and recovery of hematopoiesis after immunosuppressive therapy for hypoplastic refractory anemia with excess of blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antilymphocyte Serum; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 8; Cyclosporine; Hematopoiesis; Humans; Immunosuppressive Agents; Karyotyping; Male; Middle Aged; Remission Induction; T-Lymphocytes; Trisomy | 2001 |
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Survival Rate; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Asian People; Blood Cell Count; Bone Marrow; Cyclosporine; Disease Progression; Female; Humans; Immunosuppressive Agents; Japan; Myelodysplastic Syndromes; Treatment Outcome | 2002 |